ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IMNN / financials
PULM (36) GELS (54) ADXN (48) PCSA (39) ⌘ Pro Terminal →

Imunon Inc. (IMNN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.87 -4.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.86

Imunon Inc. (IMNN) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IMNN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IMNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Imunon Inc. (NASDAQ: IMNN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.87 (-4.38% 1D, market cap $5.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IMNN ranks #781 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IMNN compare to PULM and GELS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMNN carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PULM (Pulmatrix Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.1M) and GELS (Gelteq Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.2M). Among the 5-stock peer group, IMNN leads on earnings multiple (N/A) while IMNN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IMNN?
▼

Per IMNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000749647), Imunon Inc. generated $41.0M in revenue (-23.4% YoY), $14.5M in net income, and -$14.2M in free cash flow against $12.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.86 (-0.98%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (4)Whales (3)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
$5 Bull$1 Base$1 Bear
📬 FREE IMNN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMNN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY IMNN SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 38.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$1.07-5.6% Next Q
Q2 (-2Q)
36
Grade E$1.01-12.9% Next Q
Q3 (-1Q)
34
Grade E$0.88-1.1% Next Q
Current
31
Grade E$0.87-9.4% Hist 90D α
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMNN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMNN currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.28) and Max Pain ($0.91) forces dealer call-delta covering toward $4.83.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMNN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMNN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How IMNN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$41.0MGross Profit $21.3M (52%)Cost of Sales $19.7MOp Profit $0 (0%)OpEx (R&D/SG&A) $21.3MNet Profit$14.5M (35.3%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $58.9M
FY24
Rev $53.6M
FY25
Rev $41.0M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$41.0M52%-35.7%$14.5M-$14.2M-45%
FY 2024$53.6M52%-35.7%-$18.6M-$18.9M-45%
FY 2023$58.9M52%-35.7%-$19.5M-$19.0M-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMNN)

  • ✓Walkthrough of IMNN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IMNN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -68.93%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.83H $0.91L $0.83C $0.87VOL 132.5K
RES: $1.40SUP: $0.78SMA50: $1.28SMA200: $2.21
$4.58$3.56$2.53$1.51$0.49RES $1.40SUP $0.78$0.872026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMNN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMNN Butterfly Map → + Track IMNN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -23.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IMNN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMNN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMNN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMNN)

Health Care Rank #781 of 1015 ⚔️ PULM vs IMNN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMNN vs. PULM, GELS, ADXN, PCSA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Imunon Inc. (IMNN) ranks #781 by composite RQD confidence (31/100, grade E) and #941 by equity capitalization ($5.1M). Within this direct 5-issuer industry benchmark cohort, IMNN leads on earnings valuation at N/A trailing P/E, while IMNN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with IMNN at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IMNN ACTIVE
Imunon Inc.
E 31/100 — — -35.0% -4.38% $5.1M Benchmark Subject
PULM
Pulmatrix Inc.
D- 36/100 — — -35.0% 0.00% $5.1M /pulm-vs-imnn →
GELS
Gelteq Limited
D+ 54/100 — — — -0.10% $5.2M /gels-vs-imnn →
ADXN
Addex Therapeutics Ltd
D 48/100 — — — -3.24% $5.3M /adxn-vs-imnn →
PCSA
Processa Pharmaceuticals Inc.
D- 39/100 — — -35.0% -2.12% $5.3M /pcsa-vs-imnn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000749647 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Imunon Inc. (IMNN) reported GAAP revenue of $41.0M (-23.4% vs. FY2024 revenue of $53.6M , and -30.3% cumulative change since FY2023) , GAAP net income of $14.5M, operating cash flow of -$13.9M, and free cash flow of -$14.2M (+24.9% YoY). On the balance sheet, IMNN closed FY2025 with $12.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $41.0M $14.5M -$13.9M -$14.2M $12.3M —
FY2024 (FY) 2024-12-31 $53.6M -$18.6M -$18.9M -$18.9M $9.7M —
FY2023 (FY) 2023-12-31 $58.9M -$19.5M -$19.0M -$19.0M — —

3. IMNN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Imunon Inc. (NASDAQ: IMNN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.87 (-4.38% 1D, market cap $5.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IMNN ranks #781 in composite RQD confidence.

How does IMNN compare to PULM and GELS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMNN carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PULM (Pulmatrix Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.1M) and GELS (Gelteq Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.2M). Among the 5-stock peer group, IMNN leads on earnings multiple (N/A) while IMNN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IMNN?

Per IMNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000749647), Imunon Inc. generated $41.0M in revenue (-23.4% YoY), $14.5M in net income, and -$14.2M in free cash flow against $12.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IMNN trading relative to its 50-day, 200-day, and 52-week technical levels?

IMNN last traded at $0.87 (-4.38% on volume of 72,719 shares), positioning the stock -32.03% below its 50-day simple moving average ($1.28) and -60.63% below its 200-day simple moving average ($2.21). Across its 52-week range of $0.81 to $4.60, IMNN sits at the 1.6% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.98).

Direct Sub-Reports: IMNN RQD Cockpit IMNN 12M Forecast IMNN Earnings & Move IMNN Dividends & DRIP IMNN Insiders & 13F IMNN Whale Options IMNN Profit Sankey IMNN News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

IMNN — Imunon Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Imunon Inc. (IMNN) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.87 (-4.38% 1D, market capitalization $5.1M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Imunon Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry.. Reported revenue is — in each of FY 2023, FY 2024, and FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Imunon Inc. (IMNN) reported $41.0M in annual revenue (up from $53.6M in FY2024, -23.4% YoY) and $14.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($58.9M revenue, -$19.5M net income) through FY2025, IMNN scaled operating cash flow to -$13.9M and free cash flow to -$14.2M, backed by $12.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.81 – $4.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph reports no upstream or downstream links and no sector correlations. The VoxelDox financing and the asset transfer noted in the news feed are the only referenced dependencies, and their downstream effects are not quantified.

  • Key Question #1: Can IMNN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $41.0M and free cash flow of -$14.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is IMNN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IMNN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Imunon Inc. (IMNN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IMNN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IMNN Bull vs. Bear Conversation Board — What's Your Call at $0.87?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMNN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IMNN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $1.19 (+30.8%)
📌 Pinned Debate

A Nov. 12 ovarian cancer treatment update and the ThermoDox asset transfer could offer near-term catalysts for a stock trading at $0.83

Don't sleep on IMNN's setup in Health Care. A Nov. 12 ovarian cancer treatment update and the ThermoDox asset transfer could offer near-term catalysts for a stock trading at $0.83 with a $4.7M market cap.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (31/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

@SkepticalCFA Shorting a 3/20 institutional whale-flow stock at $0.91 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.68 (-25.3%)
Spot @ $0.91

Operating income and FCF were negative in all three reported years, and the RQD rating is 31 / E with ROIC at -35%.

I respect the product at Imunon Inc., but the stock at $0.91 is a different story. Operating income and FCF were negative in all three reported years, and the RQD rating is 31 / E with ROIC at -35%.. FCF yield is 0.0% and RQD sits at 31/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%